HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: Impact of the HLA-G 14 base pair (rs66554220) polymorphism

Haematologica

Volumn 99, Issue 5, 2014, Pages 888-896

  Rizzo, Roberta ^a   Audrito, Valentina ^b,e   Vacca, Paola ^c   Rossi, Davide ^d   Brusa, Davide ^e   Stignani, Marina ^a   Bortolotti, Daria ^a   D'Arena, Giovanni ^f   Coscia, Marta ^g   Laurenti, Luca ^h   Forconi, Francesco ⁱ   Gaidano, Gianluca ^d   Mingari, Maria Cristina ^c,j   Moretta, Lorenzo ^k   Malavasi, Fabio ^b,l   Deaglio, Silvia ^b,e  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d Azienda Ospedaliero Universitaria Maggiore della Carità   (Italy)

^e Human Genetics Foundation   (Italy)

^f REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^j UNIVERSITY OF GENOA   (Italy)

^k G GASLINI INSTITUTE   (Italy)

^l CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HLA G ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; MESSENGER RNA;

APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OVERALL SURVIVAL; PROTEIN EXPRESSION; T LYMPHOCYTE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; METABOLISM; MORTALITY; PROGNOSIS; TUMOR ESCAPE;

FEMALE; GENE EXPRESSION; HLA-G ANTIGENS; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; MALE; POLYMORPHISM, GENETIC; PROGNOSIS; RNA, MESSENGER; TUMOR ESCAPE;

EID: 84899752925     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.095281     Document Type: Article

References (37)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005; 352(8): 804-15.
2. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med. 1994; 179(3): 999-1004.
3. Benjamin D, Park CD, Sharma V. Human B cell interleukin 10. Leuk Lymphoma. 1994; 12(3-4): 205-10.
4. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008; 118(7): 2427-37.
5. Giannopoulos K, Schmitt M, Wlasiuk P, Chen J, Bojarska-Junak A, Kowal M, et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia. 2008; 22(1): 222-4.
6. D'Arena G, D'Auria F, Simeon V, Laurenti L, Deaglio S, Mansueto G, et al. A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol. 2012; 87(6): 628-31.
7. Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L, et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood. 2011; 118(23): 6141-52.
8. Rizzo R, Bortolotti D, Baricordi OR, Fainardi E. New insights into HLA-G and inflammatory diseases. Inflamm Allergy Drug Targets. 2012; 11(6): 448-63.
9. Carosella ED. The tolerogenic molecule HLA-G. Immunol Lett. 2011; 138(1): 22-4.
10. Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA. 2003; 100(15): 8856-61.
11. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-Gspecific receptor expressed on all natural killer cells. J Exp Med. 1999; 189(7): 1093-100.
12. Du L, Xiao X, Wang C, Zhang X, Zheng N, Wang L, et al. Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells. Cancer Sci. 2011; 102(7): 1272-80.
13. Diaz-Lagares A, Alegre E, LeMaoult J, Carosella ED, Gonzalez A. Nitric oxide produces HLA-G nitration and induces metalloprotease-dependent shedding creating a tolerogenic milieu. Immunology. 2009; 126 (3): 436-45.
14. Rizzo R, Rubini M, Govoni M, Padovan M, Melchiorri L, Stignani M, et al. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics. 2006; 16(9): 615-23.
15. Hviid TV, Rizzo R, Christiansen OB, Melchiorri L, Lindhard A, Baricordi OR. HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. Immunogenetics. 2004; 56(3): 135-41.
16. Rizzo R, Hviid TV, Stignani M, Balboni A, Grappa MT, Melchiorri L, et al. The HLA-G genotype is associated with IL-10 levels in activated PBMCs. Immunogenetics. 2005; 57 (3-4): 172-81.
17. Amiot L, Le Friec G, Sebti Y, Drenou B, Pangault C, Guilloux V, et al. HLA-G and lymphoproliferative disorders. Semin Cancer Biol. 2003; 13(5): 379-85.
18. Sebti Y, Le Friec G, Pangault C, Gros F, Drenou B, Guilloux V, et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol. 2003; 64(11): 1093-101.
19. Rezvany MR, Kazemi A, Hajifathali A, Kaviani S, Mellstedt H. Analysis of HLA-G gene expression in B-lymphocytes from chronic lymphocytic leukemia patients. Iran Biomed J. 2007; 11(2): 125-9.
20. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005; 105(4): 1694-8.
21. Erikci AA, Karagoz B, Ozyurt M, Ozturk A, Kilic S, Bilgi O. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology. 2009; 14(2): 101-5.
22. Deaglio S, Vaisitti T, Bergui L, Bonello L, Horenstein AL, Tamagnone L, et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood. 2005; 105 (8): 3042-50.
23. Hviid TV, Rizzo R, Melchiorri L, Stignani M, Baricordi OR. Polymorphism in the 5' upstream regulatory and 3' untranslated regions of the HLA-G gene in relation to soluble HLA-G and IL-10 expression. Hum Immunol. 2006; 67(1-2): 53-62.
24. Rizzo R, Bortolotti D, Fredj NB, Rotola A, Cura F, Castellazzi M, et al. Role of HLA-G 14bp deletion/insertion and +3142C>G polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis. Hum Immunol. 2012; 73(11): 1140-6.
25. Rebmann V, LeMaoult J, Rouas-Freiss N, Carosella ED, Grosse-Wilde H. Quantification and identification of soluble HLA-G isoforms. Tissue Antigens. 2007; 69 (Suppl 1): 143-9.
26. Fainardi E, Rizzo R, Melchiorri L, Stignani M, Castellazzi M, Caniatti ML, et al. Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol. 2007; 192(1-2): 219-25.
27. Vacca P, Martini S, Garelli V, Passalacqua G, Moretta L, Mingari MC. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. Eur J Immunol. 2013; 43(2): 550-61.
28. Vacca P, Cantoni C, Vitale M, Prato C, Canegallo F, Fenoglio D, et al. Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc Natl Acad Sci USA. 2010; 107(26): 11918-23.
29. Castellaneta A, Mazariegos GV, Nayyar N, Zeevi A, Thomson AW. HLA-G level on monocytoid dendritic cells correlates with regulatory T-cell Foxp3 expression in liver transplant tolerance. Transplantation. 2011; 91(10): 1132-40.
30. Rajagopalan S, Bryceson YT, Kuppusamy SP, Geraghty DE, van der Meer A, Joosten I, et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol. 2006; 4(1): e9.
31. Hviid TV, Hylenius S, Rorbye C, Nielsen LG. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics. 2003; 55(2): 63-79.
32. Svendsen SG, Hantash BM, Zhao L, Faber C, Bzorek M, Nissen MH, et al. The expression and functional activity of membrane-bound human leukocyte antigen-G1 are influenced by the 3'-untranslated region. Hum Immunol. 2013; 74(7): 818-27.
33. Daefler S, Krueger GR. Expression of proliferation and differentiation antigens in response to modulation of membrane fluidity in chronic lymphocytic leukemia lymphocytes. Anticancer Res. 1989; 9(2): 501-6.
34. Herishanu Y, Kay S, Dezorella N, Baron S, Hazan-Halevy I, Porat Z, et al. Divergence in CD19-mediated signaling unfolds intraclonal diversity in chronic lymphocytic leukemia, which correlates with disease progression. J Immunol. 2013; 190(2): 784-93.
35. Kshirsagar SK, Alam SM, Jasti S, Hodes H, Nauser T, Gilliam M, et al. Immunomodulatory molecules are released from the first trimester and term placenta via exosomes. Placenta. 2012; 33(12): 982-90.
36. Naji A, Le Rond S, Durrbach A, Krawice-Radanne I, Creput C, Daouya M, et al. CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood. 2007; 110(12): 3936-48.
37. D'Arena G, Laurenti L, Minervini MM, Deaglio S, Bonello L, De Martino L, et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res. 2011; 35(3): 363-8.